QIAGEN Inc.
27220 Turnberry Lane
Suite 200
Valencia
California
91355
United States
Tel: 800-426-8157
Fax: 800-718-2056
Website: http://www.qiagen.com/
About QIAGEN Inc.
QIAGEN N.V., a Netherlands holding company, is the leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated biomolecules visible. QIAGEN has developed and markets more than 500 sample and assay products as well as automated solutions for such consumables. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide. This panel includes the digene HPV Test, which is regarded as the "gold standard" in testing for high-risk types of human papillomavirus (HPV), the primary cause of cervical cancer. The company employs more than 3,100 people in over 30 locations worldwide. QIAGEN’s North American headquarters is in Germantown, Maryland and its global headquarters is located in Hilden, Germany.
Further information about QIAGEN can be found at http://www.qiagen.com/.
114 articles about QIAGEN Inc.
-
QIAGEN Inc. Drives The Development Of Companion Diagnostics With Two Key Appointments For The New Pharma Business Development Team
4/19/2010
-
QIAGEN Inc. Plans $52 Million Germantown Expansion; Qiagen to Hire 90 New Workers by 2015
4/16/2010
-
QIAGEN Inc. Acquires Exclusive Licence for Key PI3K Gene
2/8/2010
-
Pfizer Inc. and QIAGEN Inc. Unit DxS Ltd Enter Into An Agreement To Develop A Companion Diagnostic For Brain Tumor Patients
2/8/2010
-
QIAGEN Inc. Acquires ESE GmbH for up to $19 Million
1/13/2010
-
WuXi AppTec, Inc. and QIAGEN Inc. Enter into Partnership Agreement for Molecular Biomarker Development
1/11/2010
-
QIAGEN Inc. Announces Closing of the Acquisition of SABiosciences
12/14/2009
-
QIAGEN Inc. Beats Estimates, Tweaks Outlook on Test Sales
11/10/2009
-
QIAGEN Inc. and British Veterinary Laboratories Agency Expand Partnership in Veterinary Testing
11/5/2009
-
QIAGEN Inc. Acquires DxS Ltd in Deal Worth up to $130 Million -- Creating Leadership in Personalized Healthcare
9/25/2009
-
QIAGEN Inc. Acquires Additional PCR Licenses from Roche (JOBS) and Idaho Technology Inc.
9/18/2009
-
QIAGEN Inc.'s New Product Line, QIAsafe(R) DNA Blood, Has Been Co-Developed With Biomatrica
9/10/2009
-
QIAGEN Inc. Releases New Pandemic Influenza A/H1N1 Detection Kit
9/10/2009
-
QIAGEN Inc. Releases New Pandemic Influenza A/H1N1 Detection Kit
9/10/2009
-
QIAGEN Inc. Launches Complete Genotyping Solution Based on HRM Technology
9/1/2009
-
QIAGEN Inc. Q2 Profit Beats Forecasts on Test Sales
8/11/2009
-
Webcast of QIAGEN N.V.'s Second Quarter 2009 Financial Results Call Set for August 11
8/4/2009
-
QIAGEN Inc. Announces CE Mark on Next Generation Molecular Diagnostic for KRAS Analysis
6/3/2009
-
Swedish Study Shows Superior Performance of QIAGEN Inc. Pyrosequencing in KRAS Mutation Detection
6/1/2009
-
Plexus Corporation Awarded Development Contract With QIAGEN Inc.
5/29/2009